Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Pulse Biosciences (PLSE) over the last 6 years, with Q2 2025 value amounting to $13.5 million.

  • Pulse Biosciences' Gains from Investment Securities rose 1651.08% to $13.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.5 million, marking a year-over-year increase of 1651.08%. This contributed to the annual value of $830000.0 for FY2024, which is 648461.54% up from last year.
  • Pulse Biosciences' Gains from Investment Securities amounted to $13.5 million in Q2 2025, which was up 1651.08% from $1000.0 recorded in Q1 2025.
  • Pulse Biosciences' 5-year Gains from Investment Securities high stood at $13.5 million for Q2 2025, and its period low was $1000.0 during Q1 2021.
  • Over the past 5 years, Pulse Biosciences' median Gains from Investment Securities value was $5.8 million (recorded in 2021), while the average stood at $6.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 9230.77% in 2021, then surged by 55578840.0% in 2022.
  • Over the past 5 years, Pulse Biosciences' Gains from Investment Securities (Quarter) stood at $5.9 million in 2021, then dropped by 4.01% to $5.7 million in 2022, then soared by 38.47% to $7.9 million in 2023, then crashed by 89.5% to $830000.0 in 2024, then surged by 1527.89% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q2 2025, $1000.0 for Q1 2025, and $830000.0 during Q4 2024.